Skip to main content

1st birthday - reflections on the last year of blogging

A year ago today we launched the MHRA Inspectorate blog.  Now, after 12 months of activity it’s a good time to reflect on where we are and what’s to come.

Reflections on why we set up the blog

In our first post I stated that a large part of our role in the MHRA Inspectorate involves engaging with our stakeholders, you our audience.

We see a critical part of our role outside of inspections being to keep you informed of the latest changes to regulatory thinking and updates to guidance and requirements. The blog has allowed us to provide you with advice and support, promote innovation and ultimately enhance our role in protecting public health.

MHRA Inspectorate Blog 1st post

Blog impact and changes seen

Ultimately we see our blog as a way of communicating with and providing guidance to as wide an audience as possible.  Through inspections we are only able to  communicate with one organisation at a time, our symposia allow the message to be delivered to a few hundred organisations at a time, but, our blog is enabling us to  reach many thousands of organisations at a time, right across the world.  Good examples of this are our series of posts on data integrity and our post on inspecting clinical trials - The trial master file which have now been viewed well over 10,000 times each, with a number of other posts also approaching this level of activity.

In terms of outcomes, and real on the ground change, we have started to see companies adapt their approach based on what we have posted.  One great example concerns our recent post on reference safety information for clinical trials.  Although it is certainly too early to mark the post as a success in terms of overall compliance across organisations, we have received consistently good feedback during inspections in terms of how useful it has been in highlighting gaps in quality systems from both the commercial and non-commercial sector.  A specific example of this was seen during a recent inspection of a large pharmaceutical company, as through reading the post they had identified some gaps within their systems.  As a result they had already conducted a full impact assessment and made changes in the month following the blog post going live and prior to their routine GCP inspection. This avoided the site being issued with what would have been a significant inspection finding as the corrective and preventative actions had already been implemented.

Stakeholder feedback

Before starting to pen this post we reached out to a number of our stakeholders, via the members of the MHRA consultative committees and stakeholder engagement meeting (StEM) to ask how well they thought the posts were being received, and whether they’d made an impact and what more could we do.

In the main the feedback has been very supportive of the approach taken, however, there is always more that can be done.

help MHRA share knowledge and good practice

One of the key pieces of feedback received was how do we increase signposting to, raise awareness of, and expand readership of the blog - with many stakeholders saying more should be done to publicise its existence.  We are actively seeking more ways to do this and we would like to call on you, our audience, to help MHRA share knowledge and good practice by letting your colleagues (and CROs, CMOs, contract givers, contract acceptors etc.) know about this source of regulatory information.

International impact

It has been extremely pleasing that the blog has managed to attract a wide audience far beyond the UK and those countries that we undertake inspections in.  More than half our readership is based outside of the UK with the top 10 countries accessing the blog being:

  1. United Kingdom
  2. United States of America
  3. Germany
  4. India
  5. Switzerland
  6. Japan
  7. France
  8. Ireland
  9. China
  10. Denmark

MAp of the world showing the global reach

Forward look

Finally, what’s to come over the remainder of this year:

  • MHRA and PIC/S
  • MHRA and OECD
  • More on data integrity - in particular across the GXP teams
  • A series of GCP posts, including a second post on reference safety information, sponsor oversight, risk adaption, and electronic patient-reported outcome (ePRO).
  • In GMP we have posts coming on API registrations, inspection myths, and the EMA joint audit programme
  • For GPvP we will have an update on GPvP service provider inspections, RSI in post-marketing pharmacovigilance, and GPvP inspection metrics 15/16
  • 2016 Symposia highlights from across the Inspectorate

I hope you have found the posts published during the last year informative, interesting and on occasion enlightening.  We aim to build on this over the next 12 months and as always I very much look forward to hearing your thoughts on the blog and your ideas for potential posts - email us.

First birthday cake.


Don’t miss the next post, sign up to be notified by email when a new post is published on the Inspectorate blog.

Access our guidance on good practice for information on the inspection process and staying compliant.

Sharing and comments

Share this page


  1. Comment by Ayo Ogunsanlu posted on

    a very useful tool for communicating the thoughts of the Agency...its hard to believe it has been going for just one year given the benefits we have had from the information shared via this route.

  2. Comment by Lynne Byers posted on

    The MHRA has done an excellent job of informing their stakeholders of important topics and interpretations of regulations.

  3. Comment by Sue Cartwright posted on

    I have found your blog very informative, providing really clear guidance. I hope there will be many more birthdays to come.

  4. Comment by Line Lundsberg posted on

    Happy Birthday! The MHRA Blog has really been useful and an excellent way for you to share information, interpretations and findings. Thanks

  5. Comment by Lilian Ho posted on

    Happy Birthday! I have enjoyed reading the blogs, and the information has been extremely useful in my line of work. Thank you.

  6. Comment by Dr Arvind K Mishra posted on

    Happy Birthday!
    I am sure this blog helps many in pharma industry. Thanks Mark .

  7. Comment by Bob Hayes posted on

    An excellent and very worthwhile initiative - Happy Birthday!

  8. Comment by G.Sundar posted on

    An excellent and Guidance approach in GMP and related issues-Particularly trial injections;Data Integrity Part I;II: III -Very good move and expecting more Thanks and my sincere appreciationto all MHRA members

  9. Comment by Loranne Vella Zahra posted on

    Happy Birthday! Well done to the MHRA team for such a fantastic blog. I look forward to every single article, always clear and always providing excellent guidance. All the best for many more great birthdays!

  10. Comment by KVC CHAKRAPANI posted on

    MHRA is empowering the Pharma Industry & people globally by providing these blogs and latest updates w.r.t the Drug Products / Drug Substances from GMP perspective and DI topics are really worthwhile.

    Knowledge share by Blogs is an Excellent deed for the Quality n safe Product &


  11. Comment by NICK from china posted on

    I really appreciate your sharing, keep up your good job